• A new generation of DC-based immunotherapy targeting personal tumor antigens. Personal tumor antigens (e.g. neoantigens) have clinically demonstrated as promising targets for DC-based immunotherapy. Basing on above findings, we elaborated the treatment by platforms to increase personal tumor antigen presentation, and anti-tumor biomarker profiling. In addition, the manufacturing process is shorter. This innovation will significantly prolong both overall survival (OS) and progression-free survival (PFS) in refractory solid tumors such as brain tumor, liver cancer, and ovarian cancer.

  • We will launch CT101 in late 2019 dues to Taiwan Special Regulation of Cell Therapy.